Pli­ant claims ear­ly win for in­te­grin in­hibitor in chal­leng­ing IPF space — shares soar

With a num­ber of com­pa­nies — in­clud­ing Bris­tol My­ers Squibb — look­ing to drug TGF-β for a spec­trum of can­cers and fi­brot­ic dis­eases, Pli­ant Ther­a­peu­tics is tout­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER